- |||||||||| emirodatamab (AMG 427) / Amgen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 2, 2023
P1, N=64, Terminated,
N=200 --> 64 | Trial completion date: May 2025 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Feb 2023; Premature discontinuation of study, a strategic decision.
- |||||||||| emirodatamab (AMG 427) / Amgen
Trial completion date, Trial primary completion date: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 22, 2022
P1, N=200, Recruiting,
N=200 --> 64 | Trial completion date: May 2025 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Feb 2023; Premature discontinuation of study, a strategic decision. Trial completion date: May 2027 --> May 2025 | Trial primary completion date: May 2027 --> May 2025
- |||||||||| emirodatamab (AMG 427) / Amgen
Enrollment open, Enrollment change: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 18, 2022
P1, N=200, Recruiting,
Trial completion date: Dec 2025 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2027 Active, not recruiting --> Recruiting | N=130 --> 200
- |||||||||| emirodatamab (AMG 427) / Amgen
Trial completion date, Trial primary completion date: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 15, 2022
P1, N=130, Active, not recruiting,
Active, not recruiting --> Recruiting | N=130 --> 200 Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
- |||||||||| emirodatamab (AMG 427) / Amgen
Trial completion date, Trial primary completion date: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 7, 2021
P1, N=130, Active, not recruiting,
Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025 Trial completion date: Mar 2023 --> Aug 2025 | Trial primary completion date: Jan 2023 --> Aug 2025
- |||||||||| emirodatamab (AMG 427) / Amgen
Enrollment closed: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 29, 2021
P1, N=130, Active, not recruiting,
Trial completion date: Mar 2023 --> Aug 2025 | Trial primary completion date: Jan 2023 --> Aug 2025 Recruiting --> Active, not recruiting
- |||||||||| emirodatamab (AMG 427) / Amgen
Trial completion date, Trial primary completion date: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 3, 2020
P1, N=105, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Dec 2022
|
